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CI: 0.333-1.068; p0.07) which approached significance. Also, palavizumab users
incurred significantly lower all-cause costs compared to non-users ($6,206 vs.
$7,238; p0.0001). In the 2010-2011 season, 317 palavizumab users and 317 non-
users were identified. palavizumab users had a similar effect on the likelihood of
diagnoses of pneumonia (OR: 0.595; 95% CI: 0.278-1.272; p0.18) and bronchiolitis
(OR: 0.621; 95% CI: 0.346-1.112; p0.108). Also, palavizumab users incurred signifi-
cantly lower all-cause costs compared to non-users ($5,761 vs. $6,562; p0.0001).
CONCLUSIONS: When used in accordance with the 2009 American Academy of
Pediatrics Policy Statement, palavizumab appeared to reduce episodes of pneumo-
nia and bronchiolitis among children enough to reduce total program costs even
though the reductions were not statistically significant.
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OBJECTIVES: Majority of the existing research on medication adherence has fo-
cused on secondary non-adherence,with only a few studies onprimarymedication
non-adherence (PMN). PMN is defined as the failure of a patient to fill a new med-
ication prescribed by the healthcare provider. Themain objective of this study was
to formulate a comprehensive approach to capture PMN using commercial claims
datasets and to test it among pediatric population with asthma. METHODS: This
study utilized a retrospective longitudinal cohort study design involving Medicaid
claims data. The study population consisted of asthmapatients 16 years or younger
continuously enrolled for the entire study period. The patients were deemed as
PMN cases if they were found to have presence of only one claim for asthma
controller medication indicating failure to any subsequent refills. A multiple logis-
tic regression model was built to assess the predicting factors of PMN. RESULTS:
There were 8892 patients who met the inclusion criteria for this study. Of the total
8,892 patients 43% (3,846) patients stopped filling their prescription after the initial
one. African Americans (OR 0.893; CI 0.809- 0.986), other minorities (OR 0.842;
CI 0.742- 0.954), were less likely to have PMN compared to the Caucasians. Num-
ber of comorbidities decreased the odds of having PMN (OR0.801; CI 0.73- 0.879)
while fees-for-service plans (OR 1.18; CI 1.072- 1.298) increased. CONCLUSIONS:
The study successfully identified patients that could be attributed to PMN using a
population based claims dataset. The rate of PMN identified in this analysis is
alarmingly higher than any previous study. This could be explained due to two
factors: 1) The unique methodology applied in this study; 2) The study population
being drawn from Medicaid beneficiaries who are primarily belonging to low in-
come groups. Future research is warranted to address the issue of PMN.
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OBJECTIVES: Inhaled corticosteroids (ICS) are widely used in the management of
chronic obstructive pulmonary disease (COPD). Prior research suggests that COPD
patients’ access to ICS may vary by ethnicity. The objectives of the study were to
determine if there is a difference in the proportion of Hispanic and non-Hispanic
White patients taking ICS for COPD and to determine the independent predictors of
taking an ICS prescription in COPD patients.METHODS: The US Medical Expendi-
ture Panel Survey (MEPS) 2007 dataset was utilized to compare ICS prescription
patterns among patients with COPD. The sample size was restricted to Hispanic
and non-HispanicWhite patients with ICD-9CM codes for COPD between January 1
and December 31, 2007. Proportion of patients receiving ICS prescriptions within
the defined timeframewas compared by ethnicity in chi-square analysis. Multivar-
iate logistic regression was used to determine significant predictors of receiving an
ICS prescription. RESULTS: Among 1057 COPD patients included in the analysis,
16% were Hispanics, 58.5% females, and the mean age of the study population was
45.824.5. ICS were prescribed for 5.2% of Hispanic and 17.2% of non-Hispanic White
patients (p0.02). Non-Hispanic White patients with COPD had 9.37 (95% CI: 1.39;
73.28) higher odds of receiving ICS prescription thanHispanic patients independent of
age, marital status, education, smoking status, and health insurance. Among other
risk factors, only smoking was predictive of receiving a prescription for ICS (OR1.80;
95% CI: 1.03; 3.11), independent of other factors. CONCLUSIONS: Hispanic COPD
patients had substantially lower odds of receiving an ICS prescription. This
disparity in ICS prescription patterns may translate into suboptimal COPDman-
agement, a higher rate of exacerbations, and higher healthcare costs in this
growing minority population. The differences and potential disparities in ICS
use between Hispanic and non-Hispanic White COPD patients warrant further
investigation.
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OBJECTIVES: The prevalence, policies and disease control programs for Asthma
vary considerable across the country. The aim of this study is the evaluation of
inequalities in utilization of healthcare resources in Asthma diagnosed population
by using a national household survey.METHODS:We used data from 2008 Health
Supplement of the National Household Sample Survey (PNAD) conducted by Bra-
zilian Institute of Geography and Statistics (391,868 subjects). The study population
was subjects aged14 yearswith self-reportedmedical diagnosed asthma or bron-
chitis, comprising 7,509 subjects. The outcomes were presence of hospital admis-
sion and physician visit in the last year, and use of chronic medication. The out-
comes were analyzed by socio-demographic variables. Statistical analysis
comprised logistic regression for association measures, and 2 and F test to test
results independence, being significant p0.005. All analysis considered complex
plan sampling. RESULTS: In one year, among the diagnosed asthma and bronchitis
patients, 84.0% had physician visit and 12.6% had hospital admission. Also, 16%
reported use of chronic medication. The frequency of hospital admission de-
creased with the increasing of age (OR: 0.85 p0.001) and of household head edu-
cational level (OR: 0.88 p0.001). Also, hospital admission varied significantly
across the Brazilian regions (16.0% in North and Northeast to 9.8% in South
p0.001). The presence of physician visit and use of chronic medication increased
with the household educational level (OR: 1.32 p0.001 and OR:1.34 p0.001, re-
spectively) and decreased with the household overcrowding (person/bedroom)
(OR:0.89 andOR: 0.88, respectively). Furthermore, physician visit and use of chronic
medication were higher in more developed regions and white household head.
CONCLUSIONS: Patients with greater use of physician visit and medication had
lower frequencies of hospital admission. Considering the regional disparities, it is
imperative to implement effective national asthma management approaches
aimed at the appropriate target populations.
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OBJECTIVES: To compare characteristics of patients with diagnosed allergic rhini-
tis (AR) by quartiles of health care costs.METHODS: Patients 12-64 years of agewith
2 AR diagnoses or 1 diagnosis and 1 AR-related prescription claim continu-
ously eligible for 12 months before and 12 months after an AR diagnosis (1/1/2008-
3/31/2011) were identified from a privately-insured claims database
(N14,000,000). The index date was defined as the most recent AR diagnosis date
meeting the eligibility criteria, baseline period as 12 months before, and study
period as 12 months after the index date. Descriptive analyses compared demo-
graphic characteristics, co-morbidities, healthcare resource utilization and costs
(inflated to 2010 dollars) among patients in different quartiles of study period
health care costs. RESULTS: A total of 146,597 patients met the inclusion criteria.
Health care costs per patient ranged from $0-$1,118 for the lowest quartile(Q1) to
$6,349-$1,059,699 for the top quartile(Q4). Q4 patients were significantly(p0.05)
older (age 46 vs. 44[Q3], 40[Q2], 36[Q1]), had significantly higher proportion of
women (66.5% vs. 62.6%, 56.7%, 43.9%), hadmore co-morbid conditions (e.g., sinus-
itis, asthma, depression, sleep apnea), and used significantly more medications
(13.4 vs. 8.8, 6.1, 3.7) at baseline than patients in lower quartiles. During the study
period, Q4 patients had significantly higher rates of inpatient visits (26.7% vs. 3.4%,
1.2%, 0.6%), emergency department visits, outpatient/other days, and prescription
drug use, as well as higher healthcare costs ($19,519 vs. $4,186, $1,798, $544), and
they accounted for 75% of health care costs among AR patients. Additionally, Q4
patients had the highest AR-related costs ($662 vs. $521, $345, $155) and accounted
for 40% of AR-related costs among AR patients. CONCLUSIONS: Health care costs
for patients with AR were highly variable, with patients in the top quartile respon-
sible for themajority of costs. High cost AR patients were older, had higher propor-
tions of co-morbid conditions and higher health care resource utilization than
lower cost AR patients.
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OBJECTIVES: To assess the awareness amongAgateworker about silicosis, preven-
tative methods, and usage of preventative methods and factors affecting the their
usage. METHODS: It is a cross-sectional study among agate workers in Khambat
region of Gujarat State in India. The Khambat region is known for the household
agate industry, and many of workers are poorly educated and are at risk of deadly
Silicosis disease due to exposure of silica dust generated by agate grinding. This
study was conducted to assess the awareness level about silicosis, awareness
about the protective methods, worker attitude toward health, and prevalence of
actual use of protective methods to avoid silica exposure. The study was based on
questionnaire based structured interviews of 82 agate workers. RESULTS: Analysis
of the results suggests that majority of the workers (55%) were aware about the
silicosis, harmful effect of silica-dust exposure (72%), protective methods to avoid
silica-dust exposure (80%), but onlyminority of theworkers (22%) are actually using
the protective methods. Further investigation reveals the more educated workers
are more likely to use the easily available protective methods than the less edu-
cated or illiterate workers, though the awareness about of the silicosis and protec-
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